Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Total Current Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $46.1 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 92.29% to $46.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $46.1 million through Mar 2026, up 92.29% year-over-year, with the annual reading at $45.5 million for FY2025, 102.46% up from the prior year.
  • Total Current Liabilities came in at $46.1 million for Q1 2026, up from $45.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $202.8 million in Q1 2022 to a low of $3.9 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $12.3 million (2024), against an average of $30.0 million.
  • Year-over-year, Total Current Liabilities surged 337883.77% in 2022 and then crashed 96.41% in 2023.
  • MoonLake Immunotherapeutics' Total Current Liabilities stood at $7.7 million in 2022, then soared by 30.01% to $10.0 million in 2023, then surged by 125.4% to $22.5 million in 2024, then soared by 102.46% to $45.5 million in 2025, then rose by 1.4% to $46.1 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Total Current Liabilities are $46.1 million (Q1 2026), $45.5 million (Q4 2025), and $48.4 million (Q3 2025).